Barclays raised the firm’s price target on Elanco to $19 from $18 and keeps an Overweight rating on the shares. The company’s 2024 guidance and Q4 report “was balanced,” enough to hold the stock steady post a 90% raise in the last four months, the analyst tells investors in a research note. The firm believes the stock’s stock momentum will sustain as steady execution continues.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ELAN:
- Elanco Animal Health’s New Share Price & Shareholder Rights Risk – A Cause for Worry?
- ELAN Earnings: Elanco Ticks Lower on Mixed Q4 Performance
- Elanco Animal Health Reports Fourth Quarter and Full Year 2023 Results
- Elanco Animal Health (ELAN) Q4 Earnings Cheat Sheet
- Largest borrow rate increases among liquid names
Questions or Comments about the article? Write to editor@tipranks.com